Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

5839 - Biliary Tract Cancers in Portuguese families with BRCA gene mutation: a retrospective study.

Date

29 Sep 2019

Session

Poster Display session 2

Topics

Tumour Site

Hepatobiliary Cancers

Presenters

Patricia Pereira

Citation

Annals of Oncology (2019) 30 (suppl_5): v253-v324. 10.1093/annonc/mdz247

Authors

P.M. Pereira1, I.C. Oliveira1, S. Fernandes2, A.I. Clara3, I. Miguel4, S. Bento5, S. Fragoso4, S. Santos6, P. Rodrigues7, J. Parreira7, F. Rodrigues8, I. Silva7, P. Louro8, F. Vaz9, A. Luis10

Author affiliations

  • 1 Medical Oncology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E., 1099-023 - Lisbon/PT
  • 2 Clinical Genetics Department, Paediatric Hospital from Coimbra Hospital and University Center, 3000-602 - Coimbra/PT
  • 3 Clinica De Risco Familiar And Medical Oncology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E., 1099-023 - Lisbon/PT
  • 4 Clínica De Risco Familiar And Medical Oncology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E., 1099-023 - Lisboa/PT
  • 5 Clinica De Risco Familiar, Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E. (IPOLFG EPE), 1099-023 - Lisbon/PT
  • 6 Clínica De Risco Familiar, Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E., 1099-023 - Lisbon/PT
  • 7 Clinica De Risco Familiar, Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E., 1099-023 - Lisbon/PT
  • 8 Clínica De Risco Familiar, Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E., 1099-023 - Lisboa/PT
  • 9 Clinica Risco Familiar And Medical Oncology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E., 1099-023 - Lisbon/PT
  • 10 Clinica Do Risco Familiar And Medical Oncology, Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E., 1099-023 - Lisboa/PT

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5839

Background

Biliary tract cancers (BTCs) are rare. They are clinically and pathologically heterogeneous and associated with a poor prognosis. BRCA 1/2 are tumor suppressor genes responsible for a high number of hereditary breast and ovarian cancers. BRCA2 mutations are also associated with higher risk of other cancers, including prostate and pancreatic cancers. BTC-associated with BRCA mutation is still unclear. In this study, we analyzed the frequency and characteristics of BTCs in confirmed BRCA Portuguese families.

Methods

Retrospective analysis of all BRCA1/2 families registered in our multidisciplinary program since January 2000 was performed. All cases of BTCs, on the mutated side of the family were included.

Results

From 513 BRCA1/2 families, 187 were BRCA1 and 325 BRCA2. BRCA2 c.156_157insAlu - the Portuguese founder mutation - was observed in 101 families. We identified BTCs in seven BRCA2 families, five of which were c.1567_157insAlu. Overall, 7 cases of BTCs were identified (5 with pathological confirmation): 5 BRCA2 carriers and 2 first-degree relatives of BRCA2 carriers. Median age at diagnosis was 63 years, with male and female prevalence rates of 57% and 43%, respectively. Two cases of BTC were diagnosed in two female survivors of breast cancer. One female survivor of BT developed peritoneal carcinoma after prophylactic salpingo-oophorectomy. All BRCA2 families revealed a heterogeneous phenotype: 5 out of 7 families have aggregation to pancreatic and/or stomach cancers. Four patients died, three from BTC disease progression and one from peritoneal carcinoma. The other 3 patients are alive without relapse.

Conclusions

BRCA-associated BTCs are uncommon. Surveillance and prophylactic surgery reduces the risk of death from breast and ovarian cancer in BRCA2 carries allowing the diagnosis of other type of cancer during the follow-up, such as BTCs. Therefore, it is crucial the development of surveillance protocols for gastrointestinal tumours. Diagnosis of BTC-associated germline BRCA mutations might have clinical implications, expanding roles in treatment planning and allowing application of targeted therapies.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.